Page 1

SARTORIUS Press Release Aubagne , October 20 , 2021 Nine - month results of Sartorius Stedim Biotech • Sales revenue up 56.2 percent to 2,109 million euros ; underlying EBITDA margin 36.3 percent Dynamic and profitable organic growth ; significant demand momentum generated by the production of coronavirus vaccines as well as strong development of acquisitions " Forecast raised at the beginning of July for 2021 confirmed Sartorius Stedim Biotech , a leading partner of the biopharma industry , has continued to grow dynamically and profitably . For the nine - month reporting period of 2021 , the company recorded significant double - digit growth rates in sales and earnings . " In the first nine months of the year , high demand for innovative technologies for efficient biopharmaceutical manufacturing has led to the expected very dynamic development of our business . Additional momentum related to coronavirus vaccine production was significant , but not dominant . We expanded our product portfolio for use in the production of cell and gene therapeutics as well as vaccines by taking over a majority stake in CellGenix and acquiring the cell culture media specialist Xell , " said Joachim Kreuzburg , Chairman of the Board of Directors and CEO . In addition , he confirmed the forecast for the current year . " We are optimistic about the further development of our business , are driving our extensive capacity expansion and recruitment programs full steam ahead , and confirm our full - year forecast , " emphasized Kreuzburg . Group sales revenue surged by 56.2 percent to around 2,109 million euros in constant currencies ( reported : +52.9 percent ) . The majority of this growth was attributable to strong organic expansion of the core business and in all regions . In particular , business with manufacturers of biopharmaceutical medications performed very well . Beyond this , the ramp - up in coronavirus vaccine production by many customers added a good 24 percentage points to growth in sales revenue . Non - organic growth contributed by the acquisitions² was around 5 percentage points . Expanded production capacities at several company sites and overall stable , yet strained , supply chains supported this development . Order intake¹ increased even more strongly than sales revenue , surging 78.4 percent in constant currencies to 2,852 million euros ( reported : +74.1 percent ) . Part of this higher order intake was due to adapted ordering patterns of some customers who in the current situation have been placing their orders further in advance than usual . Between January and September 2021 , underlying EBITDA¹ rose by 76.1 percent to 766 million euros and thus at a significantly overproportionate rate in relation to sales . The respective margin climbed year over year from 31.5 percent to 36.3 percent . This increase was driven especially by economies of scale and by partially deferred cost development , for example , as a result of the low number of business trips and underproportionate new hires in non - production areas due to the pandemic . These trends have started to 1 | 10